Sotuvning operatsion marjasi: Replimune Group Inc (REPL)

Replimune Inc. (REPL) kompaniyasining korporativ logotipi

Replimune Group, Inc. (REPL) melanoma bilan kurashish uchun innovatsion onkolitik viruslarni ishlab chiqmoqda va yaqin orada tartibga soluvchi organlarning tasdig'i kutilmoqda. RP1 loyihalar portfelining shaffof boshqaruvi tijorat ishga tushirilishidan oldin kapitalni samarali taqsimlash imkonini beradi. Operatsion foyda marjasi biznes samaradorligi dinamikasini aks ettiradi, bunda 0.00 bazaviy qiymat sifatida qayd etilgan. Muvaffaqiyatlar yirik farmatsevtika hamkorlarining e'tiborini tortayotgan virologlar jamoasi tomonidan ta'minlanmoqda.

REPL: replimune.com Operatsion foyda normasi 04.07.2022 - 19.11.2026

Replimune Group, Inc. - tahliliy kesimlar va asosiy koʻrsatkichlar (REPL)

- kompaniyaning birjadagi kapitallashuv ko'rsatkichlari:
Kompaniyaning asosiy tahlili:REPL, Replimune
Replimune Inc. asosiy tovari

Himoyaviy portfel xarajatlarni boshqarish samaradorligini saralash orqali shakllantiriladi. Operatsion marja foizi foizlar va soliqlar to'lanishidan oldin, asosiy biznes operatsiyalardan olingan foydaning umumiy daromadga nisbatini o'lchaydi. Hozirda klinik sinovlar bosqichida bo'lgan Replimune Group, Inc. (REPL) uchun ushbu metrika tadqiqot va ishlanmalar (R&D) investitsiyalarining intensivligini aks ettiradi. Tijorat sotuvlarining yo'qligi ushbu metrika kapitalning sarflanish sur'ati ko'rsatkichiga aylanadi. Operatsion foyda farqini tahlil qilish orqali investor Replimune Group, Inc. (REPL) kompaniyasining terapevtik ustunlikka erishish yo'lidagi moliyaviy barqarorligini baholaydi.

Replimune Group, Inc. kimlar bilan raqobatlashadi

Sotuvning operatsion marjasi IBRX|IMCR - Operatsion foyda bo'yicha marjinallik|Sotuvning operatsion marjasi JANX (Janux Pharma)|Operatsion foyda koeffitsiyenti RCUS|Operatsion marja ZYME (Zymeworks)|Operatsion foyda normasi TNGX|iovance.com - Operatsion marja|Sotuvning operatsion rentabelligi Immatics Biotechnologies|Xencor, Inc. (XNCR) - Operatsion rentabellik|Compass Therapeutics - Operatsion foyda normasi|LYEL (lyell.com) - Operatsion marja|Operatsion marja Innate Pharma SA|Operatsion rentabellik pyxisoncology.com (PYXS)|CGEN: Operatsion foyda marjasi|IO Biotech Inc - Sotuvning operatsion marjasi|sutrobio.com (STRO) - Sotuvning operatsion rentabelligi|INKT - Operatsion rentabellik|werewolftx.com (HOWL) - Sotuvning operatsion marjasi|Immix (IMMX) - Operatsion rentabellik|ALXO (ALX Oncology Holdings) - Operatsion rentabellik|Sotuvning operatsion marjasi CUE|PDS Biotechnology Corporation (PDSB) - Operatsion faoliyat rentabelligi|Operatsion rentabellik Sonnet BioTherapeutics Holdings Inc. (SONN)|Operatsion marja MAIA Biotechnology Inc (MAIA)|Operatsion rentabellik Liminatus Pharma LIMN|Operatsion foyda normasi LVTX|NXTC: Sotuvning operatsion marjasi|leaptx.com - Operatsion foyda koeffitsiyenti|INTS: Operatsion marja|Sensei Biotherapeutics Inc - Operatsion foyda normasi|Sotuvning operatsion marjasi TOVX|Operatsion foyda bo'yicha sotuv rentabelligi GRTS (Gritstone bio, Inc.)|Sotuvning operatsion marjasi KA (kinetabio.com)|NEXI - Sotuvning operatsion rentabelligi|Turnstone Biologics - Sotuvning operatsion marjasi|Operatsion faoliyat rentabelligi Vaccinex Inc. (VCNX)|harpoontx.com - Operatsion marja